Potent and selective LRRK2 inhibitor (IC50 = 0.76-3.4 nM depending on assay). Exhibits >295-fold selectivity for over 300 kinases and a diverse panel of receptors and ion channels. Centrally bioavailable and active in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 379.46. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.64 mL||13.18 mL||26.35 mL|
|5 mM||0.53 mL||2.64 mL||5.27 mL|
|10 mM||0.26 mL||1.32 mL||2.64 mL|
|50 mM||0.05 mL||0.26 mL||0.53 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Fell et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J.Pharmacol.Exp.Ther. 355 397 PMID: 26407721
If you know of a relevant reference for MLi-2, please let us know.
View Related Products by Product Action
Keywords: MLi-2, supplier, leucine-rich, repeat, kinase, 2, LRRK2, inhibitors, inhibits, potent, neuroprotective, neuronal, injury, parkinson's, parkinsons, LRRK2, Tocris Bioscience
Citations for MLi-2
Citations are publications that use Tocris products.
Currently there are no citations for MLi-2. Do you know of a great paper that uses MLi-2 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.